Drug Monitoring Assess Panel, Comprehensive, Qualitative, Urine

Test Code

11878

CPT Codes
80325, 80359, 80340, 80337, 80333, 80338, 80344, 80345, 80346, 80353, 80355, 80357, 80349, 80360, 80370, 80361, 80365, 80366, 80354, 80356, 80358, 80323, 80373, 80372, 80348, 80363, 80330, 80376, 83992, 80368 (HCPCS: G0483)

Preferred Specimen

3 mL random urine in a plastic urine container

Minimum Volume

1 mL

Transport Temperature

Room temperature

Specimen Stability

Room temperature: 14 days
Refrigerated: 21 days
Frozen: 30 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Preserved urine

Methodology
Chromatography/Mass Spectrometry

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Set up: Daily; Report available: 1-2 days

Clinical Significance

In an emergency medicine or acute care setting, a definitive qualitative assessment of the presence of different drugs can be critical to patient care. Absence of an expected drug could suggest poor adherence or diversion whereas detection of a non-prescribed licit or illicit drug could indicate substance misuse or toxicity. Discrepancies between expected and actual results also call attention to potential medical factors affecting drug disposition. Drug cutoffs in this panel are targeted to detect potentially toxic or overdose situations. This assay is not intended for monitoring routine use of prescription substances.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.